The University of British Columbia Hospital MS Clinic has received over $700,000 in provincial funding to establish a CCSVI patient registry to track multiple sclerosis patients who have undergone the so-called "liberation treatment" at clinics outside Canada.
The provincial funding will be spread over three years and allows the UBC Hospital MS Clinic to establish:
•a voluntary registry to determine the number of BC residents who have had testing and/or liberation treatment
•a means to assess the benefits and complications of the treatment
•post-care treatment guidelines
The guidelines the clinic will develop will help doctors better treat those MS patients who have undergone the treatment, which uses balloon angioplasty to open blocked neck and chest veins in an effort to relieve MS symptoms.
"We have increasing numbers of patients at UBC Hospital and other clinics across the province return to Canada after having venous treatment," Dr. Tony Traboulsee, medical director of the UBC Hospital MS Clinic and assistant professor in the UBC Faculty of Medicine, said in a statement.
"Often, they are uncertain as to whether to tell their neurologist they have had the procedure, and in turn, neurologists are uncertain as to appropriate after-care. Our goal is to establish province-wide standards of care and better understand the risks and benefits for MS patients."
The liberation treatment is not currently offered in Canada but some patients have been seeking the treatment abroad.
It hinges on the theory that some patients have a condition dubbed CCSVI, or chronic cerebrospinal venous insufficiency, which narrows the veins that carry blood from the brain and spinal cord. Some believe the condition is a possible cause of MS or worsens the condition.
While research on the hypothesis is underway around the world, including in a study led by the UBC Hospital MS Clinic, many patients are seeking the treatment outside clinical trials.
Patients are then returning to B.C. with no plans for follow-up or clear instructions for care from the centres that delivered the treatment. In some cases, this puts the patient at significant risk.
"Ensuring patient safety and consistency of care is our first priority," says Dr. Traboulsee. "We also hope the data collected through this program will enhance the current research being conducted on this proposed theory of MS."
Continue reading and return here or facebook to leave a comment
The provincial funding will be spread over three years and allows the UBC Hospital MS Clinic to establish:
•a voluntary registry to determine the number of BC residents who have had testing and/or liberation treatment
•a means to assess the benefits and complications of the treatment
•post-care treatment guidelines
The guidelines the clinic will develop will help doctors better treat those MS patients who have undergone the treatment, which uses balloon angioplasty to open blocked neck and chest veins in an effort to relieve MS symptoms.
"We have increasing numbers of patients at UBC Hospital and other clinics across the province return to Canada after having venous treatment," Dr. Tony Traboulsee, medical director of the UBC Hospital MS Clinic and assistant professor in the UBC Faculty of Medicine, said in a statement.
"Often, they are uncertain as to whether to tell their neurologist they have had the procedure, and in turn, neurologists are uncertain as to appropriate after-care. Our goal is to establish province-wide standards of care and better understand the risks and benefits for MS patients."
The liberation treatment is not currently offered in Canada but some patients have been seeking the treatment abroad.
It hinges on the theory that some patients have a condition dubbed CCSVI, or chronic cerebrospinal venous insufficiency, which narrows the veins that carry blood from the brain and spinal cord. Some believe the condition is a possible cause of MS or worsens the condition.
While research on the hypothesis is underway around the world, including in a study led by the UBC Hospital MS Clinic, many patients are seeking the treatment outside clinical trials.
Patients are then returning to B.C. with no plans for follow-up or clear instructions for care from the centres that delivered the treatment. In some cases, this puts the patient at significant risk.
"Ensuring patient safety and consistency of care is our first priority," says Dr. Traboulsee. "We also hope the data collected through this program will enhance the current research being conducted on this proposed theory of MS."
Continue reading and return here or facebook to leave a comment
****************************************************************
Remain CURRENT with Multiple Sclerosis information
when registered at the MS Views and News website
..
"Providing You with 'MS Views and News', is what we do"
***************************************************************************************
.Disclaimer: 'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
.
****************************************************************
0 comments:
Post a Comment